skip to content

CEO Letter Jan 10, 2023

January 10, 2023

Dear Emmaus Family,


As we embark on the new year of 2023, Emmaus Life Sciences is filled with renewed vigor and determination in pursuit of our mission. Our efforts in the preceding year bore fruit as we achieved several significant milestones, with full marketing authorizations granted in the UAE, Qatar, and Kuwait. But our work is not yet done and the journey continues as we strive to secure approvals in the other GCC countries where sickle cell disease persists and the need is high. Additionally, we are making great strides in expanding our reach to other regions around the world where the shadow of sickle cell disease looms large, including India, South America, Bangladesh, and Pakistan, with the aim to alleviate the suffering of as many as possible.

In the coming year, we have several notable initiatives planned, including:

  1. A regular endorsement of our efforts to aid those affected by sickle cell disease by Steve Harvey on his nationally syndicated morning show
  2. A new podcast hosted by sickle cell warrior Kier Spates and produced by the renowned producer Rushion McDonald, designed to educate and raise awareness of sickle cell disease and how Endari can help.
  3. The preparation of full marketing applications for the UK, EMA, India, and the remaining GCC countries.

The real-time data on the usage of Endari has been highly encouraging, as was made evident by studies recently published in esteemed scientific journals. These studies have demonstrated that 90% of sickle cell patients are satisfied with Endari, with adherence rates of more than 70% over 18 months period.*

For more information, please refer to the following articles at your convenience:

  • Pediatric Patients with Sickle Cell Disease at Harbor-UCLA & Early Experience of L-Glutamine Therapy
  • Evaluation of Glutamine Utilization in Patients With Sickle Cell Disease J Pediatr Hematol Oncol 2023 Jan 1;45(1):e52-e55

As always, we are deeply appreciative and ever grateful for your unwavering support, as it is through your dedication that we are able to improve the lives of patients and their families.

We encourage you to stay informed by following our regular press releases, available on our website.


With sincere gratitude,

Yutaka Niihara, M.D., M.P.H.
Chairman and Chief Executive Officer

*The most common adverse reactions (incidence > 10%) in clinical studies are constipation, nausea, headache, non-crisis pain involving abdomen, back, extremities, and chest.